Vaccine makers gain amid growing concerns around bird flu

CureVac NV

07/01/2025 11:41

** Shares of vaccine maker Moderna  MRNA.O  rise ~6% to
$45.05, Novavax  NVAX.O  rise ~8% to $10.52, and U.S.-listed
shares of Germany's CureVac N.V  5CV.DE  rise 8.1% to $4.8
premarket
    ** NVAX gained 21.4% and MRNA gained 2.4% over the last 6
days 
    ** Brookline Capital Markets analyst Leah Cann said
increasing concerns around bird flu could be contributing to the
vaccine makers' recent share gains 
    ** The U.S. government in July awarded $176 million to MRNA
to complete late-stage development and testing of a pre-pandemic
mRNA-based bird flu vaccine 
    ** The U.S. on Monday reported its first human death from
H5N1 bird flu in Louisiana 
    **  Moderna lost 58.2% of its value in 2024, marking its
third straight year of losses, while NVAX snapped a two-year
losing streak gaining ~68%

 (Reporting by Mariam Sunny in Bengaluru)
 ((Mariam.ESunny@thomsonreuters.com;))